Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 10.3% – Here’s Why

Posted by Geri Gentry on Oct 22nd, 2026

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX – Get Free Report) traded up 10.3% during mid-day trading on Tuesday. The stock traded as high as $19.63 and last traded at $19.63. 70,368 shares traded hands during trading, a decline of 68% from the average session volume of 221,491 shares. The stock had previously closed at $17.79.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on SPTX shares. Wolfe Research began coverage on Seaport Therapeutics in a research report on Tuesday, July 7th. They issued a “hold” rating on the stock. JonesTrading assumed coverage on Seaport Therapeutics in a report on Wednesday, August 26th. They set a “buy” rating and a $32.00 price target for the company. Canaccord Genuity Group started coverage on Seaport Therapeutics in a report on Wednesday, October 14th. They set a “buy” rating and a $28.00 price target for the company. Raymond James Financial began coverage on Seaport Therapeutics in a research report on Friday, September 25th. They set a “strong-buy” rating and a $46.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Seaport Therapeutics in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Seaport Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $37.25.

View Our Latest Report on SPTX

Seaport Therapeutics Trading Up 2.3%

The company’s 50 day moving average is $21.66.

Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). Analysts anticipate that Seaport Therapeutics, Inc. will post -4.52 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. TRV GP VI LLC purchased a new position in shares of Seaport Therapeutics during the second quarter worth $44,769,742. Braidwell LP purchased a new stake in shares of Seaport Therapeutics in the 2nd quarter valued at $10,860,000. Citadel Advisors LLC purchased a new position in Seaport Therapeutics during the 2nd quarter valued at about $4,152,000. The Manufacturers Life Insurance Company acquired a new position in Seaport Therapeutics in the 2nd quarter valued at about $1,793,000. Finally, Alyeska Investment Group L.P. acquired a new position in Seaport Therapeutics in the 2nd quarter valued at about $1,629,000.

About Seaport Therapeutics

(Get Free Report)

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain.

Seaport’s pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care.

The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts.